FDA approves REMS for extended-release (ER) and long-acting (LA) opioids

This has been in the works for a while now. The U.S. Food and Drug Administration approved a risk evaluation and mitigation strategy (REMS) for extended-release (ER) and long-acting (LA) opioids. A key component of the REMS is training and education about the appropriate use of these options. We will be seeing CME activities focused on these issues. What is a bit surprising and confusing is that there is no mandatory requirement that prescribers take the training.

Learn more here: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm163647.htm